Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1010 participants.

Also called NCT02809131

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 1,010 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02809131
Other papers using this trial's data
  • Randomized Trial of Stand-Alone Use of the Antimicrobial Envelope in High-Risk Cardiac Device Patients Circulation. Arrhythmia and electrophysiology, 2023-05 DOI, PubMed 36960716

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02809131. Randomized; no masking; primary purpose prevention. Start 2016-04-01 (actual); primary completion 2021-03-31 (actual). Results posted on 2022-05-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.
Acronym
ENVELOPE
Condition
Sick Sinus Syndrome
Condition
Complete Heart Block
Condition
Syncope
Condition
Chronic Systolic Heart Failure
Intervention (Drug)
polymixin/bacitracin
Intervention (Drug)
cephalexin, or levofloxacin, or clindamycin
Intervention (Drug)
Saline
Lead sponsor
Vanderbilt University Medical Center (class: other)
Collaborator
Thomas Jefferson University (class: other)
Collaborator
Cooper Norcross Health (class: other)
Collaborator
Valley Health System (class: other)
Collaborator
Medtronic (class: industry)

Record details

Record id
cardio:ct-nct02809131
Content hash
9af3b1445865ad0bcbc6327d2802fa8622b638be29e79be68718e211b82963f8